Eiropas Savienība - latviešu - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekursoru šūnu limfoblastiska leikēmija-limfoma - antineoplastiski līdzekļi - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumabs - multiple mieloma - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. kopā ar bortezomib, talidomīds un deksametazona ārstēšanai pieaugušiem pacientiem, kuriem nesen diagnosticēta multiplā mieloma, kuri ir tiesīgi saņemt autologās cilmes šūnu transplantācijas. kopā ar lenalidomide un deksametazona, vai bortezomib un deksametazona, ārstēšanai pieaugušiem pacientiem ar multiplā mieloma, kuri ir saņēmuši vismaz vienu pirms terapijas. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. kā monotherapy ārstēšanai pieaugušiem pacientiem ar relapsed un ugunsizturīgo multiplā mieloma, kuru pirms terapijas iekļauts proteasome inhibitoru un imūnmodulējošu līdzekli un kas ir pierādījuši slimības progresēšanu pēdējā terapija. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumabs - multiple mieloma - antineoplastiski līdzekļi - empliciti ir norādītas kopā ar lenalidomide un deksametazona ārstēšanai multiplā mieloma pieaugušo pacientiem, kuri ir saņēmuši vismaz vienu pirms terapijas (skatīt 4. 2 un 5.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

navidea biopharmaceuticals europe ltd. - tilmanocept - radionuklīdu attēlveidošana - audzēju konstatēšana, diagnostikas radiofarmaceitiskiem preparātiem - Šīs zāles ir paredzētas tikai diagnostikas vajadzībām. radioaktīvi lymphoseek ir norādīts attēlveidošanas un intraoperative atklāšanas sentinel limfmezgli drenāžas primārā audzēja pieaugušo pacientiem ar krūts vēža, melanoma, vai lokalizētu plakanšūnu karcinomu no mutes dobuma. Ārējās attēlveidošanas un intraoperative novērtēšana var tikt veikta, izmantojot gamma noteikšanas ierīce.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - imūnsupresanti - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - antineoplastiski līdzekļi - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

janssen-cilag international nv - ustekinumabs - psoriasis; arthritis, psoriatic; crohn disease; colitis, ulcerative - imūnsupresanti - krona diseasestelara ir norādīts ārstēšanai pieaugušiem pacientiem ar vidēji smagu aktīvo krona slimība, kas ir bijusi neadekvāta reakcija, zaudēja atbildi, vai bija, kas nepanes vai nu parasto terapiju vai tnfa antagonists, vai ir medicīniskās kontrindikācijas, lai šādu terapiju. Čūlainais colitisstelara ir norādīts ārstēšanai pieaugušiem pacientiem ar vidēji smagu aktīvo čūlainais kolīts, kas ir bijusi neadekvāta reakcija, zaudēja atbildi, vai bija, kas nepanes vai nu parasto terapiju vai bioloģiskās vai ir medicīniskās kontrindikācijas, lai šādu terapiju. plāksne psoriasisstelara ir indicēts, lai ārstētu vidēji smagu vai smagu psoriāzi plāksne pieaugušajiem, kuri nespēja atbildēt, vai, kas ir kontrindikāciju, vai nepanes citas sistēmiskas terapijas, tai skaitā ciclosporin, metotreksātu un psoralen ultravioletās. bērnu plāksne psoriasisstelara ir indicēts, lai ārstētu vidēji smagu vai smagu psoriāzi plāksne bērnu un pusaudžu pacienti vecumā no 6 gadiem un vecākiem, kuri ir nepietiekami kontrolē, vai nepanes, citu sistēmisku terapiju vai phototherapies. psoriātisko arthritisstelara, atsevišķi vai kombinācijā ar metotreksātu ir indicēts, lai ārstētu aktīvo psoriātiskā artrīta ārstēšanai pieaugušiem pacientiem, ja atbilde uz iepriekšējo ne-bioloģiskie slimību modificējošiem pretreimatisma zāles (dmard) terapija ir bijusi nepietiekama.

Latvija - latviešu - Zāļu valsts aģentūra

stada arzneimittel ag, germany - paracetamols - pulveris iekšķīgi lietojama šķīduma pagatavošanai - 600 mg

Latvija - latviešu - Zāļu valsts aģentūra

sopharma ad, bulgaria - metamizola nātrija sāls - tablete - 500 mg

Latvija - latviešu - Zāļu valsts aģentūra

kalceks, a/s, latvia - metamizola nātrija sāls - Šķīdums injekcijām - 500 mg/ml